ATXN1 and cancer: However, we observed a non-significant increased frequency of ATXN1 IAs in the non-cancer patients with Parkinson’s disease compared with the cancer controls [10.4 versus 5.7%; P = 0.19, OR (95% CI): 1.91 (0.961–4.23)].